Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of HBI0201 ESO-TCRT in NY-ESO-1-positive metastatic solid tumors
MOH_2021-12-27_010493Phase 2Not yet recruiting
- Sponsor
- פרופ' מיכל לוטם
- Start
- Nov 2021
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of HBI0201-ESO in Metastatic solid neoplasm (3 arms), sponsored by פרופ' מיכל לוטם. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
HBI0201-ESO
03
Conditions
Metastatic solid neoplasm
Beyond the preview
Go deeper on MOH_2021-12-27_010493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-12-27_010493.